CD8A and melanoma: Finally, while DC‐based approaches for melanoma immunotherapy have yet to be met with the success of checkpoint blockade therapy in the clinic [34, 35], it is important to consider that these strategies may be ideally suited for use at early stages of melanoma progression, even before tumor is detectable in regional LN, as they have the potential to stimulate effector CD8+ T cell differentiation and promote the development of immunologic memory to protect against disease relapse.